Cancer Research UK representatives will attend the Salford Red Devils match against Leeds Rhinos this weekend.
The representatives will be at the home game on Saturday (August 3), with a presence in the fan zone before the match where fans will have the chance to find out more about the charity’s work and ask any questions.
There will also be the opportunity for fans to donate money to the charity around the ground, either through bucket collections or via a contactless payment.
Chelsie May, Relationship Manager for Cancer Research UK, said: “We are really excited about engaging with Salford Red Devils fans before Saturday’s big game.
“The team at Selco have been wonderful supporters of Cancer Research UK over the last couple of years and we are delighted to be extending our partnership with them through Salford Red Devils.”
Cancer Research UK, the official charity partner of Salford’s front-of-shirt sponsor Selco Builders Warehouse, funds doctors, nurses and scientists to carry out pioneering research to help provide a solution to defeating cancer.
Leading builders merchant Selco, which has branches in Salford, Ardwick, Ashton Moss and Baguley, has raised £500,000 for the charity over the last two-and-a-half years.
Cancer Research UK’s Manchester Institute is based at the University of Manchester and its work spans the whole spectrum of cancer research, from investigating the molecular basis of cancer to developing new treatments.
The Manchester Centre delivers world-leading research that accelerates the transition of lab-based discovery to the clinic for the benefit of people affected by cancer. It’s also home to one of its RadNet centres of excellence, which together form a network that aims to improve cancer survival by optimising and personalising radiotherapy.
Over the last 50 years, Cancer Research UK’s work has helped double breast cancer survival in the UK.
It was a key player in the development of radiotherapy, which now benefits more than 130,000 patients in the UK every year, while its research led to the development of the HPV vaccine, which is expected to prevent almost 90% of cervical cancers in the UK.
Recent Comments